Category Archives: TRIPS flexibilities
(Paris, October 5th 2016) European Patent Office (EPO) has taken its decision following Doctors of the World – Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
By Giulia Paravicini, Politico| Sept 19, 2016 Italy’s biggest doctors association Fnomceo wants the government to make available generic versions of pricey hepatitis c drugs so more patients can have access to them. “We want to make these drugs available for … Continue reading
By Suzanne Elvidge, BioPharma Dive| Sept 15, 2016 Dive Brief: Major trade organization PhRMA sharply criticized a decision by the Colombian government to reduce the price of Novartis’ cancer drug Gleevec (imatinib) in the country, calling the move a “harmful global precedent” … Continue reading
Submitted by Andrew Goldman on 8. September 2016, Knowledge Ecology International A German patent court has ordered a compulsory license under Section 24 of the Patent Act, allowing Merck (US) to continue to market the HIV drug raltegravir (marketed as … Continue reading
Impact of data exclusivity in Ukraine on access to affordable generic version of sofosbuvir ( direct acting antiviral – DAA used for Hepatitis C treatment) Chronology of events/facts Pharmasset originally developed Sofosbuvir. Gilead Sciences acquired Pharmasset including its Hepatititis C compounds sofosbuvir for … Continue reading
By Prabhas Ranjan, The Wire| February 2, 2016 Pricked after being sued by foreign investors under different bilateral investment treaties (BIT), India has adopted a new model. But it could impact the ongoing India-US BIT negotiations. Provoked by foreign investors suing India … Continue reading